Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
AI Risk Summary
**Alivus Life Sciences Limited – Financial Risk Summary** Alivus faces critical compliance exposure with a perfect 10.0/10 compliance risk score, creating potential SEBI enforcement action and delisting risk under BRSR Core Expansion mandates; estimated remediation costs of ₹4–14 crore represent 0.2–0.6% of revenue. Extended Producer Responsibility (EPR) liability is material (6.5/10 exposure) but remains unquantified due to unknown EPR applicability status, preventing accurate provisioning for pharmaceutical waste management obligations under the Plastic Waste Management Rules. While GHG and water intensity risks are moderate (5.0/10 each), the absence of reported Scope 1 and 2 emissions data suggests measurement gaps rather than zero impact, indicating inadequate environmental accounting systems typical of chemical/pharma manufacturers. Immediate priority: clarify EPR classification, establish emissions baseline, and close compliance documentation gaps to mitigate regulatory penalties and potential capital market restrictions.
Source: Alivus Life Sciences Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.